Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Regeneron Pharmaceuticals rose $9.70 (6.3%) to $162.69 on heavy volume. Throughout the day, two million shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 659,000 shares. The stock ranged in a price between $152.42-$163.17 after having opened the day at $158.46 as compared to the previous trading day's close of $152.99. Other companies within the Drugs industry that increased today were: Columbia Laboratories ( CBRX), up 17.5%, Amyris ( AMRS), up 16.4%, Oxygen Biotherapeutics ( OXBT), up 16.3%, and Cyclacel Pharmaceuticals ( CYCC), up 9.4%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $15.31 billion and is part of the health care sector. Shares are up 194% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, compelling growth in net income, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, United Therapeutics Corporation ( UTHR), down 15.6%, ARCA biopharma ( ABIO), down 13.3%, MEI Pharma ( MEIP), down 11.9%, and Zogenix ( ZGNX), down 8.7%, were all laggards within the drugs industry with Alexion Pharmaceuticals ( ALXN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null